Skip to main content
Fig. 6 | Journal for ImmunoTherapy of Cancer

Fig. 6

From: Sarcosine promotes trafficking of dendritic cells and improves efficacy of anti-tumor dendritic cell vaccines via CXC chemokine family signaling

Fig. 6

Analysis of murine DCs treated with sarcosine in presence of CXCR2 neutralizing antibody. a In vitro trans-well migration analysis of sarcosine treated DCs cultured with CXCR2 neutralizing antibody. Mean percentage of migrated cells were 20.13% for CCL19/21 alone, 35.5% for sarcosine+CCL19/21, 16.33% for sarcosine+CCL19/21+anti-CXCR2, and 19.46% for CCL19/21+anti-CXCR2 with CCL19/21. (p < 0.0001, one-way ANOVA, n=5). b Immunofluorescence microscopy observation of trans-well migration of sarcosine treated DCs cultured with CXCR2 neutralizing antibody. c B16F10-OVA tumor bearing animals were treated with sarcosine treated DCs versus non-sarcosine treated DCs in presence of CXCR2 neutralizing antibody. Mean difference in tumor volume was 1756 mm3 control vs. DCs, 1996 mm3 for control vs. sarcosine treated DCs and 825.4 mm3 for DCs vs. sarcosine treated DCs at day 34 (p=<0.0001, 2 way ANOVA, n=8). d GL261-GP100 tumor bearing animals were treated DCs with or without CXCR2 neutralizing antibody. Kaplan-Meier survival analysis showed that sarcosine significantly prolonged survival from naive DC vaccine treatment but this was reversed in the presence of CXCR2 neutralizing antibody (p=<0.0012, Kaplan-Meier survival analysis, n=8)

Back to article page